Brief: TCR2 Therapeutics Inc - Gavo-Cel Recommended Phase 2 Dose (Rp2d) Identification Before Year-End

TCR2 Therapeutics

20/10/2021 13:00

Oct 20 (Reuters) - TCR2 Therapeutics Inc  TCRR.O :
    * TCR2 THERAPEUTICS INC - GAVO-CEL RECOMMENDED PHASE 2 DOSE (RP2D)
IDENTIFICATION
BEFORE YEAR-END
    * TCR2 THERAPEUTICS INC - ANTICIPATED IND FILING FOR TC-510 IN 1Q22
    * TCR2 THERAPEUTICS INC - ANTICIPATES INITIATING IND-ENABLING STUDIES FOR
TC-520
WITH AN INDICATION FOCUS ON RENAL CELL CARCINOMA IN 2022
    * TCR2 THERAPEUTICS INC - ANTICIPATES IDENTIFICATION OF A LEAD CANDIDATE FOR
ITS
ALLOGENEIC PROGRAM IN 2022
    * TCR2 THERAPEUTICS INC - DEPRIORITIZED DEVELOPMENT OF TC-110
    * TCR2 THERAPEUTICS - ANTICIPATES IND FILING FOR ITS FIRST TRUC-T CELL
ENHANCED
WITH A PD1XCD28 SWITCH RECEPTOR TO BE IN 1Q22
    * TCR2 THERAPEUTICS - PLANS TO EVALUATE BUSINESS DEVELOPMENT OPTIONS TO
ENABLE
TREATMENT OF PATIENTS WITH GVHD AND OTHER AUTOIMMUNE DISEASES

Source text for Eikon:  ID:nGNX1cHJc6 
Further company coverage:  TCRR.O